Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
The most clearly defined groups who may be considered in future include individuals with: Metabolic dysfunction-associated steatotic liver disease (MASLD) particularly those with concurrent obesity, type 2 diabetes, or metabolic syndrome Metabolic dysfunction-associated steatohepatitis (MASH) the progressive inflammatory subtype associated with fibrosis and risk of cirrhosis Obesity with elevated liver enzymes (ALT/AST) where hepatic steatosis has been confirmed on imaging Type 2 diabetes with evidence of hepatic fat accumulation , where current glucose-lowering therapies have not adequately addressed liver disease Patients with significant hepatic fibrosis (stage F2 or above) represent a group with particularly high unmet need, as there are currently no licensed pharmacological treatments specifically approved for MASH in the UK
If you meet the criteria and are available, move on to Step 3
Patients experiencing memory problems or cognitive changes whilst taking Ozempic should not discontinue the medication abruptly without medical advice, as this may lead to worsening glycaemic control
In the previous paragraphs we have reviewed evidence for the clear suppression of food intake by mesolimbic GLP-1 activation
EQW is administered as a suspension with a 23-gage needle and syringe and requires reconstitution
